HOME > Investor Relations > Financial Results Highlights > New Drug Pipeline

New Drug Pipeline

New Drug Development

Taisho Pharmaceutical has positioned the four therapeutic areas of infectious diseases, orthopedic disorders, central nervous system, and metabolic diseases as its priority fields for research and development (R&D). In each of these fields, Taisho Pharmaceutical aims to discover innovative drugs that will pave the way for future growth.

Priority fields (infectious diseases/orthopedic disorders/CNS diseases/metabolic diseases)

In Japan, TS-091 as a planned indication for the treatment of central disorders of hypersomnolence, TS-152 as a planned indication for the treatment of rheumatoid arthritis, TS-141 as a planned indication for the treatment of childhood attention-deficit/hyperactivity disorder, TS-133 as a planned indication for the treatment of alopecia, and TS-142 as a planned indication for the treatment of insomnia are undergoing Phase 2 clinical trials. TS-121 and TS-134 are both undergoing clinical trials overseas in the central nervous system field.
Faced with intensifying competition in new drug discovery, we will jointly implement R&D activities with research institutions outside the Taisho Group, and with companies in Japan and overseas, as we work to enhance our drug development pipeline (lineup of drugs in development). Our goal is to discover many more new drugs, primarily in our priority fields.

New Drug Pipeline

As of Oct 30, 2017

In Japan

Phase 2
Name Application Development with
TS-091
(Oral)
Central disorders of hypersomnolence In-house
TS-152*
(Injection)
Rheumatoid arthritis In-license
TS-141
(Oral)
Childhood Attention-Deficit/Hyperactivity Disorder In-house
TS-133
(Topical)
Alopecia In-house
TS-142
(Oral)
Insomnia In-house


Overseas

Phase2
Name Target disease Development with
TS-121
(Oral)
Depression In-house
Phase1
Name Target disease Development with
TS-071**
(Oral)
Type 2 diabetes In-house
TS-091
(Oral)
Central disorders of hypersomnolence In-house
TS-134
(Oral)
Schizophrenia In-house

*TS-152: Generic name:Ozoralizumab
**TS-071: Generic name:Luseogliflozin Hydrate  In Japan: Product name: Lusefi